Dutch biopharma investor Forbion has held the first close for Forbion Growth Opportunities II at EUR 470m; the fund will invest in late-stage biopharma companies at a time when they need private capital, the GP told Unquote.
Buyer adds cosmetic surgery chain to portfolio of healthcare assets; is targeting IPO on Nordic Growth markets
Flexible remit allows EUR 2bn vehicle to invest through macroeconomic uncertainty
Fund-of-funds has made two investments to date and plans to attract further European institutional LPs
Acquisition of the Swedish customer and employee feedback platform follows a Houlihan Lokey-led sale process